What is Avalyn Pharma?
Avalyn Pharma is a biopharmaceutical enterprise dedicated to transforming the treatment landscape for rare respiratory diseases, specifically Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD). The company addresses the critical limitations of current systemic therapies, which often carry heavy side-effect profiles and restricted dosing. Through its proprietary inhaled medicine pipeline, Avalyn aims to deliver medication directly to the site of disease, thereby enhancing efficacy while minimizing systemic exposure. Its lead candidate, AP01, represents a significant advancement in inhaled pirfenidone technology, currently moving through clinical development to provide patients with improved quality of life and better long-term outcomes.
How much funding has Avalyn Pharma raised?
Avalyn Pharma has raised a total of $392.5M across 7 funding rounds:
Private Equity
$2.2M
Unspecified
$1.2M
Private Equity
$16.6M
Series A
$62M
Series B
$35.5M
Series C
$175M
Series D
$100M
Private Equity (2011): $2.2M, investors not publicly disclosed
Unspecified (2012): $1.2M, investors not publicly disclosed
Private Equity (2017): $16.6M, investors not publicly disclosed
Series A (2017): $62M featuring F-Prime Capital Partners, Edmond de Rothschild Investment Partners, RiverVest Venture Partners, Novo AS, and TPG Biotech
Series B (2020): $35.5M backed by Norwest Venture Partners, TPG Biotech, PIVOTAL BIOVENTURE PARTNERS LLC, RiverVest Venture Partners, F-Prime Capital, and Novo Holdings
Series C (2023): $175M with participation from Wellington Management, Vida Ventures, Rock Springs Capital, SR One, and Eventide Asset Management
Series D (2025): $100M led by Wellington Management, Novo Holdings, Suvretta Capital Management, TPG Biotech, F-Prime Capital, Pivotal Healthcare Partners, Xontogeny, Eventide Asset Management, RiverVest Venture Partners, Vida Ventures, Catalio Capital Management, SR One, and Norwest Venture Partners
Key Investors in Avalyn Pharma
F-Prime Capital
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term life science investments.
Wellington Management
Wellington Management is a global, independent investment management firm providing institutional clients with research-driven solutions across diverse asset classes.
What's next for Avalyn Pharma?
With the successful closure of its latest financing round, Avalyn Pharma is well-positioned to accelerate its clinical pipeline and scale its operational capabilities. The company's strategic roadmap focuses on advancing AP01 through late-stage clinical trials, aiming to establish a new standard of care for patients suffering from pulmonary scarring. As the firm transitions into a more mature phase of development, the influx of capital will likely support expanded research initiatives and the potential commercialization of its inhaled therapeutic platform. Investors remain focused on the company's ability to translate its scientific breakthroughs into tangible clinical results, marking a pivotal chapter in its growth trajectory.
See full Avalyn Pharma company page
